EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Co., Ltd., today announced the signing of a collaborative research agreement with the Ludwig Institute for Cancer Research (LICR). The multi-year agreement will fund research at LICR to develop model systems that can validate the role of novel pathways for human disease and conduct preclinical proof-of-concept studies to demonstrate the feasibility of employing antibodies to block these disease pathways, potentially leading to the development of novel therapies.
